Compare Stocks: TEVA, SNY, AMRX, and SNYNF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.28 +1.1%	$17.80	$9.49 ▼ $19.26	$5.84B	1.24	2.12 million shs	2.81 million shs
SNY Sanofi	$43.14 +1.3%	$43.95	$40.89 ▼ $52.68	$104.59B	0.35	3.41 million shs	2.96 million shs
SNYNF Sanofi	$85.51	$87.77	$80.74 ▼ $106.34	N/A	N/A	29,218 shs	164 shs
TEVA Teva Pharmaceutical Industries	$39.18 +1.7%	$35.29	$18.21 ▼ $39.70	$45.65B	0.87	6.89 million shs	5.52 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+8.59%	+4.81%	-1.85%	+11.54%	+85.63%
SNY Sanofi	+0.45%	-0.61%	-4.10%	+0.50%	-9.11%
SNYNF Sanofi	0.00%	+0.57%	-1.64%	-3.85%	-7.17%
TEVA Teva Pharmaceutical Industries	-1.39%	+4.72%	+5.70%	+22.58%	+106.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.28 +1.1%	$17.80	$9.49 ▼ $19.26	$5.84B	1.24	2.12 million shs	2.81 million shs
SNY Sanofi	$43.14 +1.3%	$43.95	$40.89 ▼ $52.68	$104.59B	0.35	3.41 million shs	2.96 million shs
SNYNF Sanofi	$85.51	$87.77	$80.74 ▼ $106.34	N/A	N/A	29,218 shs	164 shs
TEVA Teva Pharmaceutical Industries	$39.18 +1.7%	$35.29	$18.21 ▼ $39.70	$45.65B	0.87	6.89 million shs	5.52 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	+8.59%	+4.81%	-1.85%	+11.54%	+85.63%
SNY Sanofi	+0.45%	-0.61%	-4.10%	+0.50%	-9.11%
SNYNF Sanofi	0.00%	+0.57%	-1.64%	-3.85%	-7.17%
TEVA Teva Pharmaceutical Industries	-1.39%	+4.72%	+5.70%	+22.58%	+106.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.89	Moderate Buy	$20.14	10.19% Upside
SNY Sanofi	2.38	Hold	$49.50	14.74% Upside
SNYNF Sanofi	0.00	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.91	Moderate Buy	$43.10	10.02% Upside

Current Analyst Ratings Breakdown

Latest TEVA, SNY, AMRX, and SNYNF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/10/2026	SNY Sanofi	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/9/2026	AMRX Amneal Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
9/9/2026	TEVA Teva Pharmaceutical Industries	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/8/2026	SNY Sanofi	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform
9/8/2026	TEVA Teva Pharmaceutical Industries	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/7/2026	AMRX Amneal Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/4/2026	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $48.00
8/26/2026	AMRX Amneal Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/26/2026	AMRX Amneal Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$22.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.12B	1.87	$1.71 per share	10.66	($0.23) per share	-79.48
SNY Sanofi	$49.35B	2.12	$7.19 per share	6.00	$33.27 per share	1.30
SNYNF Sanofi	N/A	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$17.31B	2.64	$3.72 per share	10.52	$6.88 per share	5.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	37.31	16.93	N/A	5.05%	-584.46%	7.78%	N/A
SNY Sanofi	$8.84B	$1.91	22.59	8.16	1.28	8.66%	14.19%	7.95%	10/30/2026 (Estimated)
SNYNF Sanofi	N/A	$3.08	27.72	N/A	N/A	N/A	N/A	N/A	10/30/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$0.60	65.29	13.01	4.89	4.08%	32.64%	6.34%	11/4/2026 (Estimated)

Latest TEVA, SNY, AMRX, and SNYNF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/29/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	$0.08	$0.02	-$0.06	-$0.49	$4.02 billion	$4.14 billion
6/30/2026	Q2 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.02	N/A	-$0.49	N/A	$4.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.76	4.08%	+6.46%	92.15%	N/A
SNYNF Sanofi	$2.80	3.27%	N/A	90.78%	N/A
TEVA Teva Pharmaceutical Industries	$1.01	2.58%	N/A	168.50%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
SNY Sanofi	0.21	0.99	0.64
SNYNF Sanofi	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	1.56	0.88	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
SNY Sanofi	14.03%
SNYNF Sanofi	30.06%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
SNY Sanofi	1.00%
SNYNF Sanofi	N/A
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
SNYNF Sanofi	91,600	N/A	N/A	Not Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.17 billion	1.16 billion	Optionable

TEVA, SNY, AMRX, and SNYNF Headlines

Recent News About These Companies

Most Active Options Report: FPS, TEVA, AFL

September 16 at 11:53 AM | schaeffersresearch.com

Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ Pipeline

September 16 at 8:21 AM | finance.yahoo.com

Delhi HC orders Tax Dept to refund ₹783 Cr to Teva Israel over Ranbaxy payment

September 15 at 9:39 AM | msn.com

Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

September 15 at 8:49 AM | benzinga.com

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform

September 14 at 8:01 PM | marketbeat.com

Teva CEO on the company’s NYSE debut and what's next

September 14 at 7:37 PM | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14 at 5:00 PM | seekingalpha.com

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High - Still a Buy?

September 14 at 1:39 PM | marketbeat.com

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

September 14 at 10:01 AM | marketbeat.com

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

September 14 at 9:36 AM | finance.yahoo.com

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

September 14 at 8:03 AM | globenewswire.com

Contrasting Chugai Pharmaceutical (OTCMKTS:CHGCY) and Teva Pharmaceutical Industries (NYSE:TEVA)

September 14 at 4:15 AM | americanbankingnews.com

California State Teachers Retirement System Buys 32,425 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 13, 2026 | marketbeat.com

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

September 12, 2026 | finance.yahoo.com

National Pension Service Acquires 112,357 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 12, 2026 | marketbeat.com

Leerink Partners Begins Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

September 11, 2026 | americanbankingnews.com

Teva Prices $4.9 Bln Senior Notes To Refinance Existing Debt

September 10, 2026 | rttnews.com

Teva prices $4.9B senior notes to refinance higher-cost debt

September 10, 2026 | msn.com

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

September 10, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Prices $4.9 Billion Senior Notes Offering and Announces Conditional Redemptions

September 10, 2026 | quiverquant.comQ

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

September 10, 2026 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, SNY, AMRX, and SNYNF Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$18.28 +0.20 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$18.30 +0.02 (+0.14%)

As of 07:38 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Sanofi NASDAQ:SNY

$43.14 +0.55 (+1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$43.08 -0.06 (-0.14%)

As of 07:43 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi OTCMKTS:SNYNF

$85.51 0.00 (0.00%)

As of 09/16/2026

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Teva Pharmaceutical Industries NYSE:TEVA

$39.17 +0.65 (+1.67%)

Closing price 03:59 PM Eastern

Extended Trading

$39.17 0.00 (-0.01%)

As of 07:44 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, SNY, AMRX, and SNYNF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, SNY, AMRX, and SNYNF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, SNY, AMRX, and SNYNF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, SNY, AMRX, and SNYNF Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Sanofi NASDAQ:SNY

Sanofi OTCMKTS:SNYNF

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TEVA, SNY, AMRX, and SNYNF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TEVA, SNY, AMRX, and SNYNF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TEVA, SNY, AMRX, and SNYNF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA, SNY, AMRX, and SNYNF Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Sanofi NASDAQ:SNY

Sanofi OTCMKTS:SNYNF

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools